Treatment with lopinavir/ritonavir in heavily pretreated subjects failing multiple antiretroviral regimens in clinical practice [1]

Journal of Acquired Immune Deficiency Syndromes

Volumn 30, Issue 5, 2002, Pages 533-535

  Romano, Laura ^a   Peduzzi, Cecilia ^a   Venturi, Giulietta ^a   Di Pietro, Massimo ^a   Carli, Tiziana ^a   Corsi, Paola ^a   Gonnelli, Angela ^a   Valensin, Pier E ^a   Zazzi, Maurizio ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; LOPINAVIR PLUS RITONAVIR; PROTEINASE INHIBITOR;

CLINICAL ARTICLE; CLINICAL PRACTICE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; LINEAR REGRESSION ANALYSIS; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; TREATMENT FAILURE;

EID: 0037103631     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200208150-00010     Document Type: Letter

References (9)

1. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease
2. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients
3. The pharmacologic barrier to resistance: Differential patterns of viral evolution in protease inhibitor-naive and experienced patients during vital load rebound on Kaletra (lopinavir) therapy
4. Kaletra (lopinavir/ritonavir) in antiretroviral-naive HIV+ patients: 3-year follow-up
5. ABT-378/ritonavir (ABT- 378/R) versus nelfinavir in anti-retroviral naive subjects: Week 48 comparison in a phase III blinded randomized clinical trial
6. Performance of an in-house genotypic antiretroviral resistance assay in patients pretreated with multiple human immunodeficiency virus type 1 protease and reverse transcriptase inhibitors
7. Initial efficacy results from the Kaletra (formerly known as ABT-378/r) early-access program
8. Durable suppression of HIV+ RNA after two years of Kaletra (ABT-378/ritonavir) therapy in single protease inhibitor experienced patients
9. Kaletra (ABT-378/ritonavir) and Efavirenz: 48-week safety/efficacy evaluation in multiple PI experienced patients